Evidence map›Paper›PMID 24428686›Full record

ArticleJournal of medicinal chemistry2014

Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2'-fluoro-3'-(substituted pyridinyl)-7-deschloroepibatidine analogues.

Pauline W Ondachi, Ana H Castro, Jakub M Bartkowiak, Charles W Luetje, M Imad Damaj, S Wayne Mascarella, Hernán A Navarro, F Ivy Carroll

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Synthesis of nicotinimidamidesRSC advances · 2024
    Article
  2. Article
  3. Synthesis and preliminary evaluation of 4-hydroxy-6-(3-[Bioorganic & medicinal chemistry letters · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pauline W OndachiCenter for Organic and Medicinal Chemistry, Research Triangle Institute , P.O. Box 12194, Research Triangle Park, North Carolina 27709, United States.
Ana H Castro
Jakub M Bartkowiak
Charles W Luetje
M Imad Damaj
S Wayne Mascarella
Hernán A Navarro
F Ivy Carroll

Funding

DEVELOPMENT OF LIGANDS FOR NICOTINIC RECEPTORSR01DA012001 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI CARROLL, FRANK IVY · 1999 to 2012
$4.8M
NIDA NIH HHS DA12001NIDA NIH HHS R01 DA012001
6 · The paper itself

Abstract

2'-Fluoro-3-(substituted pyridine)epibatidine analogues 7a-e and 8a-e were synthesized, and their in vitro and in vivo nAChR properties were determined. 2'-Fluoro-3'-(4″-pyridinyl)deschloroepibatidine (7a) and 2'-fluoro-3'-(3″-pyridinyl)deschloroepibatidine (8a) were synthesized as bioisosteres of the 4'-nitrophenyl lead compounds 5a and 5g. Comparison of the in vitro nAChR properties of 7a and 8a to those of 5a and 5g showed that 7a and 8a had in vitro nAChR properties similar to those of 5a and 5g but both were more selective for the α4β2-nAChR relative to the α3β4- and α7-nAChRs than 5a and 5g. The in vivo nAChR properties in mice of 7a were similar to those of 5a. In contrast, 8a was an agonist in all four mouse acute tests, whereas 5g was active only in a spontaneous activity test. In addition, 5g was a nicotine antagonist in both the tail-flick and hot-plate tests, whereas 8a was an antagonist only in the tail-flick test.

Indexed as

AnalgesicsAnimalsBody TemperatureBridged Bicyclo Compounds, HeterocyclicContraindicationsFemaleMaleMiceNicotinic AgonistsNicotinic AntagonistsOocytesPainPatch-Clamp TechniquesPyridinesRadioligand AssayRatsAnalgesicsBridged Bicyclo Compounds, HeterocyclicepibatidineNicotinic AgonistsNicotinic AntagonistsPyridinesReceptors, Nicotinic

Identifiers

PMID24428686
PMCPMC3983394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.